Literature DB >> 11573133

The role of pendrin in iodide regulation.

L Fugazzola1, N Cerutti, D Mannavola, G Vannucchi, P Beck-Peccoz.   

Abstract

Recent advances in human genetics have catalyzed the attention on Pendred's syndrome and its disease-gene, PDS. Studies on the expression of the PDS gene and on the function of its encoded protein, which has been named pendrin, are currently in progress. Consistent with the Pendred's syndrome phenotype, which is characterized by thyroid dysfunction associated to deafness, PDS expression has been demonstrated in the thyroid and in the inner ear. Despite its high homology to known sulfate transporters, pendrin has been shown to transport iodide and chloride, but not sulfate. Thus, it is probably devoted to regulate, at the apical membrane where it has been immunolocalized, the flux of iodide from the thyroid cell to the colloid space. The function of pendrin in the inner ear is not well understood, but it seems to function also at this level as an anion transporter. Indeed, a pronounced PDS expression has been detected in structures of the inner ear, such as the membranous labyrinth and the endolymphatic duct and sac. At this level, the possible role of pendrin could be the maintenance of the appropriate ionic composition of the endolymph. Although many questions remain to be answered, these recent achievements concerning the putative role of pendrin aid to better understand the genetic basis of the peculiar phenotype of Pendred's syndrome, which associate the dysfunction of two so different organs such as the thyroid and the inner ear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573133     DOI: 10.1055/s-2001-11008

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Mutation analysis of SLC26A4 for Pendred syndrome and nonsyndromic hearing loss by high-resolution melting.

Authors:  Neng Chen; Lisbeth Tranebjærg; Nanna Dahl Rendtorff; Iris Schrijver
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

2.  Association of SLC26A4 mutations with clinical features and thyroid function in deaf infants with enlarged vestibular aqueduct.

Authors:  Satoshi Iwasaki; Koji Tsukamoto; Shinichi Usami; Kiyoshi Misawa; Kunihiro Mizuta; Hiroyuki Mineta
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

3.  Interleukin-13 increases pendrin abundance to the cell surface in bronchial NCI-H292 cells via Rho/actin signaling.

Authors:  Annamaria Russo; Marianna Ranieri; Annarita Di Mise; Silvia Dossena; Tommaso Pellegrino; Emilia Furia; Charity Nofziger; Lucantonio Debellis; Markus Paulmichl; Giovanna Valenti; Grazia Tamma
Journal:  Pflugers Arch       Date:  2017-04-04       Impact factor: 3.657

4.  Functional assessment of allelic variants in the SLC26A4 gene involved in Pendred syndrome and nonsyndromic EVA.

Authors:  Alejandra Pera; Silvia Dossena; Simona Rodighiero; Marta Gandía; Guido Bottà; Giuliano Meyer; Felipe Moreno; Charity Nofziger; Concepción Hernández-Chico; Markus Paulmichl
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

5.  Molecular Features of SLC26A4 Common Variant p.L117F.

Authors:  Arnoldas Matulevičius; Emanuele Bernardinelli; Zippora Brownstein; Sebastian Roesch; Karen B Avraham; Silvia Dossena
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

6.  Pathogenic substitution of IVS15 + 5G > A in SLC26A4 in patients of Okinawa Islands with enlarged vestibular aqueduct syndrome or Pendred syndrome.

Authors:  Akira Ganaha; Tadashi Kaname; Kumiko Yanagi; Kenji Naritomi; Tetsuya Tono; Shin-ichi Usami; Mikio Suzuki
Journal:  BMC Med Genet       Date:  2013-05-24       Impact factor: 2.103

7.  The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.

Authors:  Carla Colombo; Emanuela Minna; Chiara Gargiuli; Marina Muzza; Matteo Dugo; Loris De Cecco; Gabriele Pogliaghi; Delfina Tosi; Gaetano Bulfamante; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  J Exp Clin Cancer Res       Date:  2020-11-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.